Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class compounds that selectively target G protein-coupled receptors for oncology. The first lead compound to result from this program is ONC201, an orally active DRD2 small molecule antagonist that is well-tolerated and effective against advanced cancers. The company has completed a successful Phase I study in solid tumors and is focused on a first approval of ONC201 for patients with H3 K27M-mutant high grade glioma, an aggressive subtype of brain cancer. Oncoceutics and collaborative groups have received grants from the National Cancer Institute, the U.S. Food and Drug Administration, the Pennsylvania Department of Health, and The Musella Foundation. In addition, outside interest in the company’s portfolio has resulted in several R&D alliance agreements between Oncoceutics and leading comprehensive cancer centers, including The University of Texas MD Anderson Cancer Center and the Fox Chase Cancer Center. The company has established a robust intellectual property position, covering ONC201 and the imipridone platform, including more than 20 issued patents. Oncoceutics’ pipeline includes ONC201 in multiple trials at various stages, and several analogs with improved and differentiated profiles in preclinical testing. ONC206, Oncoceutics second development candidate entered clinical development in late 2019.